abrdn plc Sells 741,343 Shares of Pfizer Inc. (NYSE:PFE)

abrdn plc trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,737,487 shares of the biopharmaceutical company’s stock after selling 741,343 shares during the quarter. abrdn plc’s holdings in Pfizer were worth $98,763,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. Matisse Capital bought a new stake in shares of Pfizer in the 4th quarter valued at $202,000. Alliance Wealth Advisors LLC UT boosted its stake in shares of Pfizer by 5.6% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 12,571 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 669 shares during the last quarter. Vantage Point Financial LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $485,000. Holistic Planning LLC boosted its stake in shares of Pfizer by 11.2% in the 4th quarter. Holistic Planning LLC now owns 51,573 shares of the biopharmaceutical company’s stock valued at $1,368,000 after purchasing an additional 5,209 shares during the last quarter. Finally, Lazari Capital Management Inc. boosted its stake in shares of Pfizer by 45.0% in the 4th quarter. Lazari Capital Management Inc. now owns 32,229 shares of the biopharmaceutical company’s stock valued at $855,000 after purchasing an additional 10,005 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

PFE opened at $26.23 on Tuesday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $148.62 billion, a price-to-earnings ratio of 35.44, a PEG ratio of 0.66 and a beta of 0.64. The company’s fifty day moving average price is $26.27 and its two-hundred day moving average price is $27.85.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.56%. Pfizer’s dividend payout ratio is presently 232.44%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research reports. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.